Amicus (FOLD) Receives a Buy from Cowen & Co.
Cowen & Co. analyst Ritu Baral maintained a Buy rating on Amicus (FOLD) on October 1 and set a price target of $31.00. The company’s shares closed last Friday at $17.17, close to its 52-week high of $17.67.
According to TipRanks.com, Baral is a 5-star analyst with an average return of 13.1% and a 48.6% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Milestone Pharmaceuticals, and ACADIA Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Amicus with a $23.67 average price target.
See today’s analyst top recommended stocks >>
Based on Amicus’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $62.35 million and GAAP net loss of $52.49 million. In comparison, last year the company earned revenue of $44.13 million and had a GAAP net loss of $84.55 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.